Medscape Medical News, February 05, 2025 Alert Ozempic Receives New Indications in Chronic Kidney Disease Semaglutide is now approved for reducing the risk for worsening kidney disease and ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity or overweight.

initiation of chronic kidney replacement therapy (dialysis or kidney transplantation), and death from kidney disease or death from CV disease. Findings showed treatment with semaglutide reduced ...

(HealthDay News) — For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION), according to a ...

The five stages of chronic kidney disease (CKD) indicate how well the kidneys are working, ranging from stage 1 (mild kidney ...

Semaglutide was a top-selling drug in 2023 ... and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Ozempic’s parent company, Novo Nordisk, is the only pharmaceuti ...

The Food and Drug Administration has determined that the shortage of Wegovy® (semaglutide) and Ozempic® (semaglutide) is resolved.

“Chronic kidney disease is a global healthcare problem ... GLP-1 agonists – LEADER with liraglutide and SUSTAIN-6 with semaglutide – in which we included important renal endpoints.

New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk’s OZEMPIC Approval Heat Up the Chronic Kidney Disease Therapeutic Market | DelveInsight The FDA’s recent approval of OZEMPIC ...